Compass Pathways stock advances as COMP360 data support 2027 plans

Compass Pathways plc (GB00BKLLQZ68) is targeting a 2027 COMP360 launch after new clinical data showed benefits lasting up to 12 months. The Nasdaq-listed stock closed at USD 15.00 on September 22, 2026, according to the latest quoted market snapshot.

COMP360 data extend to one year

As Yahoo Finance reported on September 22, 2026, Compass said about 25 percent of patients achieved a clinically meaningful response after one COMP360 dose, while the response rate reached about 40 percent after two doses. Follow-up data indicated that the benefit could remain durable for up to 12 months.

The figures relate to the company's Phase 3 COMP005 and COMP006 programs. According to MarketBeat on September 22, 2026, the trials produced a difference of just under four points from baseline on the Montgomery-Asberg Depression Rating Scale at the six-week primary endpoint.

FDA filing remains the next hurdle

The clinical signal supports the company's 2027 launch objective, but the commercial timetable still depends on regulatory execution. MarketBeat reported on September 22, 2026, that Compass was preparing for an FDA filing while continuing discussions with payers after the 26-week COMP005 data release.

For investors, the key comparison is the gap between one and two administrations: the reported clinically meaningful response rate rose from about 25 percent to about 40 percent. The same report said common adverse events included nausea, headache and fatigue, generally resolving within one or two days, leaving tolerability and treatment logistics as important parts of any future rollout.

Stock closes at USD 15.00

Compass Pathways stock closed at USD 15.00 on Nasdaq on September 22, 2026. The market level provides the current reference point while the 2027 launch objective and the 12-month durability result define the company's present investment narrative.

More news and analyses on Compass Pathways stock